Post-traumatic stress disorder

Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’s Subjects

Retrieved on: 
Wednesday, October 5, 2022

Alzamend is also pursuing AL001 for the treatment of bipolar disorder, MDD and PTSD.

Key Points: 
  • Alzamend is also pursuing AL001 for the treatment of bipolar disorder, MDD and PTSD.
  • As the safety and tolerability of AL001 would need to be tested in healthy and elderly adults before Alzamend could initiate later-stage testing of AL001 for bipolar disorder, MDD and PTSD, the addition of healthy and elderly adults to the on-going AL001-02 clinical trial would expedite the timing of further clinical trials.
  • Alzamend will test AL001 in four healthy adult and elderly adult cohorts of eight subjects under MAD conditions.
  • AL001 has the potential to deliver benefits of marketed lithium carbonate while mitigating or avoiding current toxicities associated with lithium.

KetaMD Expands Access to Breakthrough Ketamine Therapy in Florida to Battle the Growing Mental Health Crisis and Shortage of Mental Health Care Providers

Retrieved on: 
Tuesday, October 4, 2022

KetaMD is committed to battling the growing mental health crisis and alleviating the growing shortage of mental health care providers in Florida and across America, both issues further exacerbated by the COVID-19 pandemic.

Key Points: 
  • KetaMD is committed to battling the growing mental health crisis and alleviating the growing shortage of mental health care providers in Florida and across America, both issues further exacerbated by the COVID-19 pandemic.
  • Mental Health Crisis by the Numbers:
    1 in 5 U.S. adults experience mental illness each year.
  • Over 6.3 million people in Florida live in a community that does not have enough mental health professionals.
  • Florida ranks 49th in the nation for access to mental health care, according to Mental Health America.

LIFESTANCE HEALTH GROUP, INC. (NASDAQ: LFST) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against LifeStance Health Group, Inc. (NASDAQ: LFST)

Retrieved on: 
Tuesday, October 4, 2022

NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or otherwise acquired the common stock of LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (NASDAQ: LFST) pursuant and/or traceable to the Registration Statement and Prospectus (collectively, the “Registration Statement”) issued in connection with LifeStance’s June 10, 2021 initial public stock offering (the “IPO”). The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1933.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1933.
  • LifeStance is one of the nations largest providers of virtual and in-person outpatient mental health care.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

“Breakthrough Solutions for the Mental Health Epidemic” Set for October 19 at the 2022 National Workers’ Compensation and Disability Conference

Retrieved on: 
Thursday, September 29, 2022

A team of workers compensation experts will showcase innovations in mental health treatment with a groundbreaking, experiential presentation at this years National Workers Compensation and Disability conference.

Key Points: 
  • A team of workers compensation experts will showcase innovations in mental health treatment with a groundbreaking, experiential presentation at this years National Workers Compensation and Disability conference.
  • We hope that people leave our session not only educated but inspired and ready to try something new.
  • As nurses, we are well aware of the impact psychosocial and mental health issues have on an injured worker and their recovery, says Thomas.
  • We partner with employers, third-party administrators, insurance companies and government agencies in managing workers compensation and health, auto and liability services.

Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type

Retrieved on: 
Thursday, September 29, 2022

The product candidate is designed to treat mild to moderate dementia of the Alzheimers type.

Key Points: 
  • The product candidate is designed to treat mild to moderate dementia of the Alzheimers type.
  • ALZN002 is a proprietary active immunotherapy product, which means it is produced by each patients immune system.
  • The submitted IND supports initial deployment of a clinical trial, ALZN002-01, a first-in-human, randomized, double-blind, placebo-controlled, parallel-group, Phase I/IIA clinical trial.
  • ALZN002 immunotherapy is intended to treat patients diagnosed with Alzheimers by inducing the patients own antibodies.

Point32Health Announces Three Finalists in First Annual Innovation Challenge Symposium

Retrieved on: 
Wednesday, September 28, 2022

The company's peer-based delivery network addresses health inequities while driving resilience, improving member experience, and reducing costs.

Key Points: 
  • The company's peer-based delivery network addresses health inequities while driving resilience, improving member experience, and reducing costs.
  • Point32Health initiated this challenge to facilitate discovery, development, and implementation of innovative solutions that improve health care for its members and communities, increase affordability, and improve the overall healthcare experience.
  • The Innovation Challenge Symposium is an opportunity for one or more of these companies to work with Point32Health on a pilot or program, funded by the insurer.
  • Point32Health is a leading health and wellbeing organization, delivering an even-better health care experience to everyone in our communities.

Edgar Ross, M.D., Renowned Pain Expert and Director of Pain Management at Harvard University, Joins Harvard MedTech’s Medical Advisory Board

Retrieved on: 
Tuesday, September 27, 2022

Edgar Ross, M.D., one of the nation's most renowned pain experts, is joining the Medical Advisory Board of Harvard MedTech .

Key Points: 
  • Edgar Ross, M.D., one of the nation's most renowned pain experts, is joining the Medical Advisory Board of Harvard MedTech .
  • We are honored to have one of the nations foremost authorities on pain management join Harvard MedTechs Medical Advisory Board, said Gerry Stanley, M.D., Chief Medical Officer, Harvard MedTech.
  • Like Harvard MedTech, he is committed to reversing the opioid crisis and ensuring non-addictive treatments become more mainstream in the management of injured workers.
  • Dr. Ross is considered one of the leading pain management physicians in the world and is recognized for his contributions to the field of pain management across the globe.

atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01

Retrieved on: 
Tuesday, September 27, 2022

NEW YORK and BERLIN, Sept. 27, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), which is developing EMP-01, a 3,4-methylenedioxy-methamphetamine (MDMA) derivative for the treatment of post-traumatic stress disorder (PTSD) and other indications, announced today its Phase 1 study has received regulatory and ethics approvals required from Medsafe and HDEC, respectively, to initiate participant enrollment.

Key Points: 
  • Evidence shows that two-thirds of patients either do not respond or have only a partial response to these medications.
  • These modifications are designed to separate the entactogenic effects of MDMA from some of the known side effects, specifically its stimulant-associated effects.
  • Data on MDMA-assisted psychotherapy strongly suggests its potential for the treatment of PTSD, said Glenn Short, Senior Vice President, Early Development of atai Life Sciences.
  • atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders.

BetterLife Files Comprehensive Patent for BETR-001 and Other LSD Derivatives

Retrieved on: 
Tuesday, September 27, 2022

BetterLife is currently developing a new composition of 2-bromo-LSD (BETR-001) covered by these patent filings.

Key Points: 
  • BetterLife is currently developing a new composition of 2-bromo-LSD (BETR-001) covered by these patent filings.
  • BETR-001 is a second-generation LSD derivative molecule that does not cause hallucinations, and therefore is not subject to global controlled substance regulations.
  • BetterLife is already in advanced stages of GMP manufacturing of BETR-001 and completing the necessary preclinical IND-enabling studies for BETR-001.
  • BetterLife expects to file the BETR-001 IND and start Phase 1, in healthy subjects, in H1 of 2023.

LIFESTANCE HEALTH GROUP, INC. (NASDAQ: LFST) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against LifeStance Health Group, Inc. (NASDAQ: LFST)

Retrieved on: 
Tuesday, September 27, 2022

NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or otherwise acquired the common stock of LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (NASDAQ: LFST) pursuant and/or traceable to the Registration Statement and Prospectus (collectively, the “Registration Statement”) issued in connection with LifeStance’s June 10, 2021 initial public stock offering (the “IPO”). The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1933.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1933.
  • LifeStance is one of the nations largest providers of virtual and in-person outpatient mental health care.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.